[EN] QUATERNARY SALT CCR2 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CCR2 A BASE DE SELS QUATERNAIRES
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2006012135A1
公开(公告)日:2006-02-02
Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.
Formula (I)的四价盐化合物或其药学上可接受的形式,其为CCR2拮抗剂,可用于预防、治疗或改善CCR2介导的炎症综合征、疾病或症状。
Quaternary salt CCR2 antagonists
申请人:Lagu Bharat
公开号:US20060293379A1
公开(公告)日:2006-12-28
Quaternary salt compounds of Formula (I)
or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.
[EN] NOVEL BRIDGED BICYCLOALKYL-SUBSTITUTED AMINOTHIZOLES AND THEIR METHODS OF USE<br/>[FR] NOUVEAUX AMINOTHIAZOLES À SUBSTITUTION BICYCLOALKYLE PONTÉS ET LEURS PROCÉDÉS D'UTILISATION
申请人:UNIV TEMPLE
公开号:WO2018136766A1
公开(公告)日:2018-07-26
The present invention includes novel bridged bicycloalkyl-substituted aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis
申请人:Madrid Peter
公开号:US20130150369A1
公开(公告)日:2013-06-13
Benzotriazine doxides are disclosed as drugs targeting
mycobacterium tuberculosis
, including novel compounds of formula I:
Benzotriazine doxides被披露为针对结核分枝杆菌的药物,包括公式I的新化合物。
ASYMMETRIC PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES
申请人:Caille Seb
公开号:US20110178307A1
公开(公告)日:2011-07-21
The invention provides two process for synthesizing substituted aminothiazolone compounds as inhibitors of 11-β-hydroxy steroid dehydrogenase type 1. The processes allow the stereoselective synthesis of the desired compounds without the use of stoichiometric amounts of chiral catalysts.